http://www.ybe.com.tw/ 明達實業股份有限公司為醫療保健公司，設立於1986年，致力於保健、疾病治療與造福人群。 我們的目標在於引進先進的高科技醫療產品，來改善、治療患者的疾病，使患者病痛得以緩解或痊癒，進而增進患者的健康和生活品質。我們的責任是提供多樣化的高品質產品給需要的病患，特別是腫瘤的分子檢測和用藥，我們具備了多年的專業經驗，已讓廣大的病患得到最大的幫助。為了 明達實業股份有限公司 更寬廣的未來，我們將以專業服務延伸企業目標，並加以實踐"明查病因，藥達病癒"的公司願景，期許將明達之醫療事業帶到社會之各個角落。 Yeong Being Enterprises Co., Ltd. (YBE) was founded in 1986, managing distribution pharmaceutical products in Taiwan, and also doing export business to Korea and other Asia countries.YBE has been marketing oncology products and orphan drugs in Taiwan over ten years, distribute the products of Chiron Corporation, namely Proleukin® (aldesleukin), Tobi® (Tobramycin solution for inhalation)and Cardioxane® (Dexrazoxane hydrochloride)since 1999.  Now YBE is working with Novartis after Chiron was acquired by Novartis in 2005, selling Proleukin product very well every year, even that Metastatic renal cell carcinoma and malignant melanoma are rare cancers in Asians.   YB is also contracted as BTG distributor in Taiwan for selling unique products as DigiFab® (digoxin immune Fab (ovine)) and Voraxaze®(glucarpidase).   Hence, YBE is very experienced and gain good connections with the medical professionals in drug and medical device fields, also co operate with SSPL in France for female contraceptive sponge which we have contracted selling and manufacturing in Taiwan. As the economy and health expenditure is expanding rapidly, YBE foresees there is much room for the growth of pharmaceutical products in Taiwan for the coming years.   In 2012, YBE provides a new service for breast cancer patients is Symphony Breast Cancer Suite (Personalized Breast Cancer Genomic Profile), which is an advanced genomics platform for tumor gene expression profiling and built microarray assay tests that can determine whether an individual patient is at high or low risk for breast cancers recurrence, helping physicians more accurately tailor cancer treatments. zh 智邦生活館 版權所有 Foresight v0.3.2 RSS 2.0 Generator 智邦生活館 網站代管 Fri, 07 Nov 2025 09:24:44 CST Fri, 07 Nov 2025 09:24:44 CST 智邦生活館 版權所有 10080 525275 Thu, 06 Nov 2025 15:51:49 +0800   https://mammaprint.com.tw/ https://mammaprint.com.tw/ http://www.ybe.com.tw/hot_525275.html 440005 Tue, 06 Sep 2022 17:19:57 +0800 http://www.ybe.com.tw/hot_440005.html http://www.ybe.com.tw/hot_440005.html 440004 Tue, 06 Sep 2022 17:15:46 +0800 http://www.ybe.com.tw/hot_440004.html http://www.ybe.com.tw/hot_440004.html 440002 Tue, 06 Sep 2022 16:58:24 +0800 http://www.ybe.com.tw/hot_440002.html http://www.ybe.com.tw/hot_440002.html 390277 Wed, 28 Apr 2021 16:01:59 +0800 http://www.ybe.com.tw/hot_390277.html http://www.ybe.com.tw/hot_390277.html 322211 Thu, 01 Aug 2019 15:51:02 +0800   http://www.ybe.com.tw/hot_322211.html http://www.ybe.com.tw/hot_322211.html 85130 Tue, 06 May 2014 16:19:21 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測解開乳癌腫瘤基因的奧秘協助「個人化」乳癌治療利用先進乳癌基因組分析微陣列技術(Microarray)，分析與乳癌腫瘤相關的基因組和基因間相互反應對腫瘤生長變化與演進的發展，榮獲美國FDA五項認證，為乳癌病患尋求預後和預測治療之基因檢測。  MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測通過美國FDA核准&榮獲多項國際治療指引推薦● 美國FDA 510K五項核准● 歐洲合格認證● 美國國家癌症資訊網(NCCN) -NCCN唯一認可：Mammaprint是乳癌淋巴結陰性及1~3顆陽性的多基因檢測中，為第一類最高階醫學認證● 美國臨床腫瘤醫學會(ASCO)● St.Gallen聖加侖國際乳癌專家共識● AJCC 美國癌症聯合會● ESMO 歐洲腫瘤醫學會MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測是結合各項檢驗所分析出完整病理的檢測報告-Breast Cancer Recurrence Signature分析70個基因的表現，辨別乳癌腫瘤屬於高風險，需要接受手術後的輔助治療，或者是低風險，可避免不必要的化療。MammaPrint分析腫瘤細胞從生長到演化轉移細胞內的70個基因及465個參考基因訊息經研究分析的結果可分別出高或低二種風險：  低風險  指數MPI ≦ 0.355 以賀爾蒙療法為主，可避免化療。   指數MPI ＞0.355 可避免化療和也不需賀爾蒙療法。  高風險  建議接受化療，必要時外加賀爾蒙療法來幫助這類病人，改善乳癌DMFS機率(無遠端轉移生存期)  ※檢測報告採用清楚的二分法，呈現一個明確的結果，沒有惱人不明確的「中度復發指數」。Molecular Subtyping Signature分析80個基因，判定乳癌亞型Basal type(基底細胞型)、Luminal type(管狀型)或ERBB2type(HER2陽性)。其中Luminal type(管狀型)配合MammaPrint的結果，能判定低風險的Luminal A與高風險的Luminal B，協助醫師和病患選擇更好的治療方向。儘管一般檢驗分析以免疫組織化學/IHC方法學，檢驗ER/PR/HER2受體是陰性或陽性來表示受體是否存在，但是這樣是無法確認其功能具有活性存在，所以BluePrint檢測分析不僅僅看蛋白質受體的表現，而是要確認基因是否具有功能性才能辨別出真正乳癌亞型治療分類，打造真正適合您的藥物治療，達到個人化精準治療的目的。MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測檢測結果明確分析出腫瘤是屬於高風險或低風險低風險：可避免不必要的化療高風險：做化療有效益補充說明:Oncotype DX安可待乳癌腫瘤基因表現檢測，有高、中、低復發風險三種指數：低復發風險：＜18中復發風險：18~30(可以接受化療或不必接受化療，容易造成醫療上的困擾)高復發風險：≧30MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測沒有罹癌期別的限制：適用於每一個期別的乳癌患者沒有罹癌期別的限制，包含1~3個淋巴結浸潤、HER2陽性患者、腫瘤T0-T2(小於5公分)或停經婦女皆可接受檢測，精確提供乳癌的生物特性，幫助患者及醫師了解化療對患者腫瘤治療的效益和制定最佳治療用藥方案。Grade 1：細胞分化良好，癌細胞仍像正常細胞，通常緩慢生長。 檢體再經MammaPrint分析仍有20%屬高風險，提供醫師積極治療資訊，避免治療不足發生。Grade 2：細胞中度分化，癌細胞不像正常細胞，通常生長較快速。 檢體再經MammaPrint分析精確判讀有50%屬低風險，可以避免過度治療現象產生。Grade 3：細胞分化不良，癌細胞和正常細胞截然不同，癌細胞快速生長。 檢體再經MammaPrint分析有15%屬低風險，可以避免過度治療現象產生。 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測瞭解研究開發公司Agendia NV │ 來自荷蘭阿姆斯特丹的介紹! MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測我們將協助您瞭解檢測的申請作業流程 │ 希望您發現檢測流程簡單、高效且易於瞭解。 如欲索取欣扶妳手冊，請點入「留言板」，敬請於留言欄中留下您的聯絡方式，如單位、姓名及聯絡電話....等，以方便連絡確認。謝謝！  http://www.ybe.com.tw/hot_85130.html http://www.ybe.com.tw/hot_85130.html 295047 Thu, 15 Nov 2018 17:17:58 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測預估與乳癌細胞復發有關的70種基因，對未來5到10年的復發率進行預測協助醫師評估部分患者是否可能不必再接受化療，以避免化療產生的副作用或患者發生治療量不足的可能由荷蘭科學家研發出的MammaPrint+BluePrint 欣扶妳乳癌腫瘤基因雙效檢測，會針對手術切除癌細胞的乳癌患者體內，與癌細胞有關的70種特定基因包括癌細胞的七個步驟相關的基因進行電腦分析，多數乳癌婦女在手術後都會持續進行化療，以避免乳癌復發；但研究已指出，許多婦女即使不接受術後化療，乳癌也不會復發。癌細胞生長的七步驟：1)成長分裂 → 2)血管增生 → 3)侵犯局部 → 4)穿透血管 → 5)在血液循環存活 → 6)穿出血管 → 7)在新環境適應甚至轉移與癌細胞有關的70種特定基因1) 成長分裂IGFBP5, TGFB3, ESM1, RARRES3, PITRM1, EXT1, EXTL3, SCUBE2, EBF4, CDC42BPA, CDCA7, CDCA7L, GMPS, MELK, RFC4, WISP1, HRASLS, BBC3, DTL, FBXO31, EGLN1, GNAZ, MTDH, FLT1, ECT2, DIAPH3, NUSAP1, AKAP2, NDC8O, PRC1, ORC6L, CENPA, DCK, CCNE2, MCM6, QSOX2, STK32B2) 血管增生COL4A2, FLT1, FGF18, MMP93) 侵犯局部FLT1, TGFB3, IGFBP5, FGF18, RARRES3, CDCA7L, WISP1, DIAPH3, ALAP2, CDC42BPA, PALM2, DCLK2, NMU, NMUR1, NMUR24) 穿透血管COLA2, FLT1, MMP9, TGFB3, MTDH, DIAPH3, PALM2, DCLK2, NMU, NMUR1, NMUR25) 在血液中循環存活穿出血管COL4A2, FLT1, MMP9, TGFB3, DIAPH3, PALM2, DCLK2, NMU, NMUR1, NMUR26) 穿出血管COLA2, FLT1, MMP9, TGFB3, MTDH, DIAPH3, PALM2, DCLK2, NMU, NMUR1, NMUR27) 在新環境適應甚至轉移MMP9, COL4A2 http://www.ybe.com.tw/hot_295047.html http://www.ybe.com.tw/hot_295047.html 297214 Mon, 10 Dec 2018 16:10:05 +0800 隨著人們對腫瘤早診意識的覺醒，應該選擇哪種乳癌基因檢測?選擇前您應該認識的乳癌檢測工具「擁有70個基因的檢測系統」早期乳腺癌化療的困境近年來隨著人們對腫瘤早期發現早期治療意識的覺醒，尤其是在40歲以上的女性人群中大力推廣乳腺標靶檢測，大量的I、II期乳腺癌能夠在腫塊小於5cm，未出現腋下淋巴結轉移或有少量轉移時被檢測出。這類病人的預後較好，經手術切除和放射治療或化療之後，5年生存率得到大幅提升。但在實際的臨床實踐中仍然存在著是否給病人進行化療的困境有大約25%的乳癌患者，在手術切除之後，如果未輔助以化療，腫瘤會發生轉移復發；而對於另外一部分病人，單純的手術切除而不加化療，5-10年內也不會出現腫瘤的轉移復發。然而實際上卻有75%的病人選擇了化療，這意味著有將近一半的病人承受了額外的化療之苦。目前臨床上仍是以腫瘤患者的臨床病理特徵來作為主要標準區分不同預後的患者，例如腫瘤越大、數目越多，則認為病人越需要化療，已經出現腋下淋巴結轉移的病人比沒有轉移的病人更需要化療，這種分類方法相對比較粗放，臨床實踐過程中也發現該種分類準確性有限，有相當一部分被認為是低復發風險的患者後期也出現了復發轉移。在這種情況下，迫切需要一套更精確的分類方法。70基因檢測系統的出現和驗證20世紀末，人類基因組計劃完成，「後基因組」時代來臨之際，生物晶片作為一種高通量研究方法被被用來進行腫瘤「基因表達譜」的研究。在這個過程中，利用基因晶片的研究發現了許多與腫瘤的轉移復發相關的基因，通過評估這些基因在腫瘤組織中的表達水平，從而能夠對腫瘤細胞的轉移復發能力做出比腫瘤的病理特徵更精準的判斷。2002年，荷蘭癌症研究院的研究人員開發了一套乳腺癌多基因檢測Panel，其運用cDNA基因晶片技術，檢測78例淋巴結陰性、年齡 http://www.ybe.com.tw/hot_297214.html http://www.ybe.com.tw/hot_297214.html 86135 Tue, 15 Apr 2014 11:57:37 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測解開妳必須知道的病理報告用語目前診斷乳癌使用一些參數來決定腫瘤的本質，常出現在病理報告中的一些用語：1. Tumor size：腫瘤大小2. Lymph node：淋巴結受侵犯的數目3. Grade：細胞分化Grade ~ ，數字愈大分化愈差4. Ki-67：細胞增殖指數，比例愈高癌細胞分裂愈快，一般 http://www.ybe.com.tw/hot_86135.html http://www.ybe.com.tw/hot_86135.html 86148 Mon, 05 May 2014 10:50:59 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測由荷蘭國家癌症研究院和分子醫學權威Agendia公司共同合作開發可以預估與乳癌細胞復發有關的70種基因，對未來5到10年的復發率進行預測 由荷蘭國家癌症研究院(Het Nederlands Kanker Instituut- Antoni van Leeuwenhoekziekenhuis，NKI-AVL)和分子醫學權威Agendia公司合作，歷經20年研究比對兩組腫瘤細胞樣本的人類基因組後所研發。  研究人員歷經20年研究比對由乳癌腫瘤轉移過程中，找出關鍵70個基因的特徵經由35,000位婦女被醫師診斷為乳癌確診病例，這些婦女經手術切除腫瘤後，完全都沒有接受化療或荷爾蒙治療(輔助治療)，有些患者5年內復發，有些患者5年後「沒有」復發。研究人員歷經20年研究比對兩組腫瘤細胞樣本的人類基因組，分析了人體內25,000個基因，再將這些資料經過篩選及精確的計算，確定了乳癌腫瘤轉移過程中，關鍵70個基因的特徵。  http://www.ybe.com.tw/hot_86148.html http://www.ybe.com.tw/hot_86148.html 293657 Fri, 02 Nov 2018 09:53:25 +0800 NCCN更新治療指引，將MammaPrint納入乳癌檢測1級美國國家癌症資訊網(NCCN)和美國臨床腫瘤醫學會(ASCO)針對lymph-node positive患者，更新的NCCN治療指引中推薦的唯一基因組乳癌檢測工具美國國家癌症資訊網(NCCN)更新治療指引，將MammaPrint納入乳癌檢測1級NCCN推薦Agendia的MammaPrint為高水平的乳癌檢測，對於早期乳癌患者ER+，lymph-node negative和lymph-node positive（LN+1-3）MammaPrint現在是美國國家癌症資訊網(NCCN)和美國臨床腫瘤醫學會(ASCO)針對lymph-node positive患者，更新的NCCN治療指引中推薦的唯一基因組乳癌檢測工具。Agendia的公司今天宣布，美國國家癌症資訊網(NCCN)更新了其臨床實踐治療指引為包括MammaPrint 70-基因乳癌復發風險測試，有助於確定乳癌在lymph-node negative或positive(LN + 1-3)的ER+乳癌患者中復發的可能性。通過這些更新，MammaPrint獲得了基因組測試的最廣泛指導，具並且是同類測試中唯一具有1級的lymph-node negative和lymph-node positive疾病證據的檢測。NCCN美國國家癌症資訊網(National Comprehensive Cancer Network)治療指引是公認的癌症治療臨床標準，是由領先的癌症中心的臨床醫生和研究人員提供的。NCCN根據現有證據修訂推薦的實踐治療指引，最終目標是改善患者護理和結果。MammaPrint納入NCCN治療指引是基於具有里程碑意義的臨床試驗MINDACT的數據，這是一項隨機，前瞻性的III期試驗，評估了MammaPrint試驗的臨床效用。該研究於2016年發表在“ New England Journal of Medicine”上，發現近50％的患者最初根據臨床和病理因素確定其癌症復發風險高，因此而接受化療的患者實際上是低風險的。MammaPrint分析了與乳癌復發相關的70個最關鍵的基因，將每個乳癌患者分類為診斷後早期10年內發生轉移的“低風險”或“高風險”。您可以訪問www.nccn.org查看NCCN更新的治療指引。Agendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) GuidelinesAgendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) GuidelinesThe NCCN recommends Agendia’s MammaPrint® breast cancer test with the highest level of evidence for early-stage breast cancer patients with estrogen receptor-positive, lymph-node negative and lymph-node positive (LN+ 1-3) MammaPrint is now the only genomic breast cancer test that is recommended in guidelines by the NCCN and the American Society of Clinical Oncology (ASCO) for lymph-node positive patients The updated NCCN Guidelines – released during Breast Cancer Awareness Month– mark the fifth positive international guideline update for MammaPrint since 2017IRVINE, CALIF., U.S., AMSTERDAM, NETHERLANDS – 9 October 2018 – Agendia, Inc., a world leader in precision oncology, today announced that the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines to include the MammaPrint® 70-gene Breast Cancer Risk-of-Recurrence Test, which helps determine the likelihood breast cancer will recur in patients with estrogen receptor-positive breast cancer that is either lymph-node negative or positive (LN+ 1-3). With these updates, MammaPrint has received the broadest guidance of any genomic test, and is the only test of its kind with Level 1 evidence for both lymph-node negative and lymph-node positive disease.The NCCN Guidelines, which are the recognized clinical standard for cancer care, are created by input from clinicians and researchers at leading cancer centers. The NCCN revises recommended practice guidelines according to current evidence with the ultimate goal of improving patient care and outcomes.MammaPrint’s inclusion in the NCCN guidelines is based on data from the landmark clinical trial, MINDACT, a randomized, prospective, Phase III trial, which evaluated the clinical utility of the MammaPrint test. The study, published in the New England Journal of Medicine in 2016, found that almost 50 percent of patients initially identified with a high risk of their cancer recurring based on clinical and pathological factors and thus candidates for chemotherapy, were in fact Low Risk according to the MammaPrint test and unlikely to benefit from it.MammaPrint analyzes the 70 most important genes associated with breast cancer recurrence to classify each breast cancer patient into “Low Risk” or “High Risk” of developing metastases within the first 10 years after diagnosis.You can access the updated NCCN guidelines at www.nccn.org. http://www.ybe.com.tw/hot_293657.html http://www.ybe.com.tw/hot_293657.html 68894 Mon, 05 May 2014 10:53:28 +0800 MammaPrint Breast Cancer Recurrence Signature乳癌復發風險檢測 │ 分析70個基因的表現，辨別乳癌腫瘤本質分析70個基因的表現，辨別乳癌腫瘤本質不好的屬於高風險患者，需要接受手術後的輔助治療；乳癌腫瘤本質好的低風險患者，可避免不必要的化療。◎低風險(Low Risk)： 乳癌患者手術後沒有做任何 輔助治療 (包括化療和荷爾蒙治療)，10年內90% 的機率不會復發。雌激素受體陽性者，接受荷爾蒙治療10年內無復發機率高達95%。 ◎高風險(High Risk)： 建議乳癌患者需接受化療，必要時外加荷爾蒙治療來幫助此類患者，降低乳癌 發的機會。MammaPrint 乳癌復發風險檢測 產品發表與研發過程影片  http://www.ybe.com.tw/hot_68894.html http://www.ybe.com.tw/hot_68894.html 96546 Fri, 12 Oct 2018 10:52:28 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測被專家們列入美國NCCN治療指引美國NCCN guidelines內容摘錄： 乳癌患者可以"predictions of clinical outcome"ER-positive及ER-negative乳癌患者可以"predictions of clinical outcome"                MammaPrint is approved by the FDA to assist in assignment of women with ER-positive or ER-negative breast cancer into a high versus low risk for recurrence.MammaPrint is listed as "New Treatment Implications" in NCCN Guidelines:With a median follow-up of 5 years, among patients at high clinical risk and low genomic risk,the rate of survival without distant metastasis in this group was 94.7% among those not receiving chemotherapy.Among patients with 1-3 positive nodes,the rates of survival without distant metastases were 96.3% in the chemotherapy group and 95.6% in the no-chemotherapy group.Therefore, the benefit of chemotherapy may be smaill in this group.關於NCCN    http://www.ybe.com.tw/hot_96546.html http://www.ybe.com.tw/hot_96546.html 252197 Tue, 07 Nov 2017 12:05:35 +0800 (備註：個別患者各有其特殊狀況應由患者及其主治醫師共同決定。) http://www.ybe.com.tw/hot_252197.html http://www.ybe.com.tw/hot_252197.html 293198 Mon, 29 Oct 2018 18:01:18 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測分子醫學權威Agendia公司 │ 一家尖端的腫瘤基因檢測及精準醫療的國際企業Agendia通過分析人類全部基因組，實現無偏差基因選擇，研發出各種乳癌檢測產品，包括     Agendia公司是位於荷蘭的一家尖端的腫瘤基因檢測及精準醫療的國際企業，致力於研發並銷售基因檢測相關的診斷產品，協助醫師制訂複雜的治療方針；除此以外，Agendia公司更聯合各大型製藥企業、領先的癌症醫學中心和醫療相關的學術機構共同研發更多關於腫瘤領域的診斷檢測。MammaPrint乳癌復發風險檢測 + BluePrint分子亞型檢測上述這兩種基因檢測產品都是基於微陣列技術而研發出，而Agendia還有其它更多的基因檢測產品尚在研發測試中。Agendia位於荷蘭阿姆斯特丹(Amsterdam)和美國加州(California)兩間實驗室，不只榮獲美國FDA認證，還獲得ISO 13485與美國病理學會(The College of AmericanPathologists，CAP)，以及其他方性政府機關的認證，值得您的信賴！Ref: Eur. J. Neurosci., 28, 2365-2370,2008 https://www.agendia.com/licenses-and-accreditations/About AgendiaFrom day one, Agendia was founded on the belief we could improve the quality of life for cancer patients everywhere. Today, our genomic tests are achieving this goal with a broad and growing global customer base, including many major hospitals and clinical institutions. Through every step, we continue to stay focused on providing the innovation and dedication that helps patients live better lives.Here are a few of our company highlights:2003—Agendia was founded as a spin-off of the Netherlands Cancer Institute in Amsterdam2004—We launched our flagship breast cancer risk of recurrence test, MammaPrint, in Europe2007—MammaPrint became the first IVDMIA* to gain 510(k) clearance from the FDA, and has since received six additional FDA clearances2007—We launched MammaPrint in the US2010—We introduced our second breast cancer test, BluePrint, a molecular subtyping test2016—The landmark MINDACT trial was published, demonstrating the clinical utility of MammaPrint with the highest possible level of evidence (level 1A)2017—MammaPrint was recommended in prestigious clinical practice guidelines including ASCO, the only test of its kind recommended for both lymph node-negative and lymph node-positive patients2017—Publication of the STO-3 trial demonstrated that patients with a MammaPrint Late recurrence (20-year) Low Risk result had excellent breast cancer-specific survival, 20 years after diagnosis with little or no hormone therapy2018—The MammaPrint and BluePrint Kit attained the CE mark, allowing leading cancer centers across Europe to run these tests in their own labs using their existing next-generation sequencing (NGS) technology†2018—MammaPrint and BluePrint were launched to patients and physicians in China http://www.ybe.com.tw/hot_293198.html http://www.ybe.com.tw/hot_293198.html 65466 Tue, 06 May 2014 16:20:39 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測通過美國FDA（食品藥物管理局）MammaPrint獲得五項認證美國食品藥物管理局FDA在2007年批准MammaPrint欣扶妳乳癌腫瘤基因檢測，使用在乳癌患者的確診病例手術後的檢體做檢測，來預測乳癌是否會在5或10年內復發。(認證編號:K101454、K080252、K070675、K081092、K141142)1. 用乳癌腫瘤基因表現來評估乳癌復發與遠端轉移風險的體外診斷檢測2. 美國加州與荷蘭阿姆斯特丹兩大實驗室品質管制，基因晶片合併DNA及RNA品質鑑定符合基因檢測標準3. 高密度微陣列掃描技術4. 新鮮檢體RNARetain保存技術5. 突破過去的檢測年齡限制，檢測年齡最高可達87歲6. FFPE(福爾馬林固定石蠟包埋檢體)可應用於MammaPrint分析70個基因乳癌復發風險檢測 http://www.ybe.com.tw/hot_65466.html http://www.ybe.com.tw/hot_65466.html 293587 Thu, 01 Nov 2018 10:39:11 +0800 我們將為您說明檢測的申請作業流程 以下流程圖將協助您進一步的瞭解檢測流程，關於申請、收集、送出、檢測分析及報告的產出  http://www.ybe.com.tw/hot_293587.html http://www.ybe.com.tw/hot_293587.html 85206 Mon, 18 Nov 2013 11:37:08 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測讓低風險的她改變治療計畫以遠離化療副作用來自美國眾議院(United States House) The Medical Technology Caucus (MTC)支持舉辦的記者會，會中Lisa感謝MammaPrint，讓低風險的她可以遠離化療副作用，重新回職場，維持豐富的社交生活，同時仍可兼顧好母親的角色。 (備註：個別患者各有其特殊狀況應由患者及其主治醫師共同決定。) http://www.ybe.com.tw/hot_85206.html http://www.ybe.com.tw/hot_85206.html 94744 Tue, 15 Apr 2014 17:00:01 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測獲得2013聖加倫S't Gallen Consensus國際乳癌專家會議共識乳癌專家：未來兩年內早期乳癌治療一致共識。聖加侖St.Gallen腫瘤學會議是全球專家研討有關早期乳癌臨床治療的專業會議，全球共有95個國家3,700個成員參加，其中有來自21個國家51個國際的乳癌專家成員來擬定對治療的建議。在2013年3月在瑞士聖加倫舉行第13屆國際乳癌專家會議，經過討論後以投票的方式形成專家對乳癌手術，賀爾蒙治療，放射性治療，化學治療，分子診斷亞型等多個方面的具體問題達成未來兩年內早期乳癌治療一致共識。關於聖加侖St.Gallen腫瘤學會議about the foundation St.Gallen Oncology Conferences (SONK)St.Gallen Oncology Conferences (SONK) is a private charitable and tax-exempted educational foundation according to Swiss law, registered and supervised by the Department of Interiors of the Swiss Canton (State) of St.Gallen in Eastern Switzerland.St.Gallen Oncology Conferences (SONK) consists of two different programs:The international conference part in English language, organizes since 1978 repeatedly international breast cancer conferences (Primary Therapy of Early Breast Cancer) including the highly respected, now biannually, international breast cancer treatment consensus recommendations since 1978/82 as well as repeated international conferences on “Clinical Cancer Prevention” since 1998 and also international symposia about other topics.The coordination secretariat of the Deutschsprachig-Europäische Schule für Onkologie (deso), an educational program for oncologists and oncology nurses in German.St.Gallen Oncology ConferencesSt.Gallen Oncology Conferences SONK is organising international conferences. The events deal withbreast cancergastrointestal cancerclinical cancer prevention and geneticscancer patients care issues (nursing oncology, supportive care, psycho-oncology).The congresses have built up a high impact in the international medical world over the past 20 years. Especially the consensus meeting about early breast cancer therapies influences treatments globally.Presentations and abstracts of the meetings are published world wide in renowned medical journals.The first breast cancer conference organised by St.Gallen Oncology Conferences was held 1978. SONK has been legally founded 1996 as a charitable foundation in order to provide a stable organisational framework for the events. The foundations' aim is to promote knowledge and exchange of experiences within the medical community in order to increase a high quality of treatment for cancer patients worldwide. Initiator of SONK is Prof. Hans-Jörg Senn MD, who has created and built up the organisation. http://www.ybe.com.tw/hot_94744.html http://www.ybe.com.tw/hot_94744.html 239541 Mon, 17 Jul 2017 16:47:17 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測列入ASCO美國臨床腫瘤學會《臨床實踐指南》ASCO(American Society of Clinical Oncology)美國臨床腫瘤學會於2017年7月10日，在《臨床實踐指南》發表了題為“Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer”使用生物標誌對早期浸潤性乳癌婦女的全身性輔助治療決策指引，再次肯定了MINDACT試驗的臨床應用價值，您可經由下列ASCO網站連結一睹最新聚焦亮點：ASCO(American Society of Clinical Oncology)美國臨床腫瘤學會發表：https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/breast-cancer#/9746JCO(Journal of clinical oncology)臨床腫瘤學雜誌亦同步發表：http://ascopubs.org/doi/full/10.1200/JCO.2017.74.0472ASCO推薦ER/PgR–positive, HER2-negative, node-negative, or one to three positive nodes臨床高危險群病患，使用MammaPrint可進行化療必要性之決定。其中針對one to three positive nodes病患群，可謂是MINDACT帶來的患者福音，也是唯一ASCO推薦之高水準MammaPrint基因組測試。 http://www.ybe.com.tw/hot_239541.html http://www.ybe.com.tw/hot_239541.html 68830 Mon, 05 May 2014 11:12:32 +0800 BluePrint Molecular Subtyping Signature分子亞型檢測 │ 分析80個基因，判定乳癌亞型其中Luminal type(管狀型)配合MammaPrint的結果，能判定低風險的Luminal A與高風險的Luminal B ，協助醫師和患者選擇更好的治療方向。(1) Basal type (基底細胞型) (2) Luminal type (管狀型)(3) ERBB2 (HER2陽性)。  http://www.ybe.com.tw/hot_68830.html http://www.ybe.com.tw/hot_68830.html 219332 Thu, 19 Jan 2017 15:04:42 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測21個基因檢測無法解決我的問題  http://www.ybe.com.tw/hot_219332.html http://www.ybe.com.tw/hot_219332.html 218087 Mon, 09 Jan 2017 11:14:23 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測獲得MINDACT臨床試驗的最高水平臨床證據的支持2016年美國癌症醫學會年會(ASCO)發表了MINDACT試驗的期中報告，這個研究總共招募6693個早期乳癌(荷爾蒙受體陽性，HER2陰性且淋巴結轉移數量為0-3顆)經手術治療後的患者，同時使用兩種方式(臨床評估與基因檢測評估)來評斷病人復發風險高低；臨床風險的評估方式是使用Adjuvant！Online的程式，輸入患者腫瘤的臨床和病理指標來計算其復發風險，可分為臨床高風險(c-high)和臨床低風險(c-low)；另一個評估方式是採用腫瘤的基因檢測(共評估70個基因的MammaPrint)，可藉此將患者分為基因高風險(g-high)和基因低風險(g-low)；經由這兩項評估方法可以將患者分成四群，在臨床、基因皆為低風險(c-low/g-low)的組別，無論是否接受術後化療，5年的存活率皆高達98% (顯然不需要化療)；兩者皆為高風險(c-high/g-high)的病人，即使術後接受輔助化療，長期存活率也只有90.6% (顯然需要化療)；最能受益於MammaPrint基因檢測的是臨床高風險但基因低風險(c-high/g-low)的這一群，過去的標準做法是讓這群患者儘量接受術後輔助化療；但從MINDACT試驗中發現，臨床高風險且基因低風險(c-high/g-low)的這群病人如果隨機分派為兩組，一組接受術後化療，另一組沒有化療；這兩組的5年存活率並沒有統計學上的差異(95.9% vs. 94.4%)。以較簡單的方式去理解，就是以前被認定要接受術後化療的臨床高風險(c-high)早期乳癌患者，若接受MammaPrint檢測證實為基因低風險(c-high/g-low)，則明顯可免除術後化療，這並不會導致長期存活率降低。可嘉惠患者以免除化學治療所帶來的副作用和長期併發症。(備註：個別患者各有其特殊狀況應由患者及其主治醫師共同決定。)(文字說明資料來源擷取自：http://web.tccf.org.tw/lib/addon.php?act=post&id=3957)2016年發表在《新英格蘭醫學期刊》上具有裏程碑意義的MINDACT試驗發現根據MammaPrint的檢測結果，最初根據臨床和病理因素診斷為癌症復發高風險而因此需要化療的患者中，近50%實際上為低風險，而且並不太可能從化療中受益。MINDACT試驗結果可能使全球每年超過10萬名女性早期乳癌患者避免不必要的化療和副作用並可能節省醫療所須費用。 http://www.ybe.com.tw/hot_218087.html http://www.ybe.com.tw/hot_218087.html 86139 Thu, 17 Apr 2014 11:23:10 +0800 獲得美國NIH國家衛生研究院肯定臨床試驗I-SPY 2：篩選乳癌患者進入乳癌新藥研發臨床試驗的唯一乳癌腫瘤基因分析的檢測工具。美國FDA和美國國家衛生研究院(National Institutes of Health,NIH)傾力贊助的乳癌新藥研發之臨床試驗I-SPY 2，致力於加速乳癌新藥「個人化治療」的開發平台，以MammaPrint+BluePrint 欣扶妳乳癌腫瘤基因雙效檢測做為篩選乳癌患者進入乳癌新藥研發臨床試驗的唯一乳癌腫瘤基因分析的檢測工具。 I-SPY 2:Investigation of Serial Studies to Predict Your Therapeutic Response with lmaging and Moleculalysis http://www.ybe.com.tw/hot_86139.html http://www.ybe.com.tw/hot_86139.html 86930 Mon, 05 May 2014 11:41:52 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測Agendia獲得MammaPrint乳癌復發檢測和BluePrint分子亞型檢測的CE標誌MammaPrint + BluePrint Kit現已獲得CE認證，使公司能夠在歐洲將該設備商業化。Agendia EMEA商務副總裁Marjolaine Baldo博士說：“獲得MammaPrint和BluePrint Kit的CE標誌是一個重要的里程碑。歐洲著名的癌症中心將首次使用現有的NGS儀器在自己的實驗室中運行MammaPrint和BluePrint。因此，患者將能夠更好地獲得這些重要測試以及為她們個人化乳癌管理帶來的顯著益處。“為我們團隊、合作夥伴和共同驗證中心的努力得到激勵，對於奉獻精神和專業知識感到自豪，他們需要分工協力的解決方案，不知疲倦地開發、驗證並將這一重要設備推向市場。我們期待與領先的乳癌中心合作，為他們提供這些工具，使他們能夠在內部設立並提供乳癌復發風險測試。MammaPrint分析了70個與乳癌復發最相關的基因，以提供低或高風險的癌症復發結果，而BluePrint分析80個基因，將患者的乳癌分子亞型分析。這種新設備結合了MammaPrint和BluePrint，可以幫助醫生為患者提供個人化的治療管理決策，通過識別患有早期乳癌的女性，她們在五年內基因組處於低或高風險的遠處轉移。MammaPrint和BluePrint Kit是Agendia現有的MammaPrint和BluePrint測試的基於RNA測序的版本，目前在通過CLIA和CAP認證位在加利福尼亞州歐文和荷蘭阿姆斯特丹的Agendia實驗室集中進行。該試劑盒是與Agilent Technologies合作開發的，使用他們的SureSelect靶向富集系統和Bluebee，後者為臨床醫生提供安全便捷的數據處理解決方案。Agendia首席醫療官William Audeh博士說：“具有里程碑意義的MINDACT試驗證明了MammaPrint測試的臨床應用。結果顯示，根據臨床病理因素，46％的患者根據臨床病理因素確定復發風險高，因此是輔助化療的典型候選人，MammaPrint將其重新歸類為低風險，表明他們是不太可能從化療中受益。“乳癌是女性中最常見的癌症，在歐洲影響八分之一，每年有近500,000例新病例，確定以前選擇用於化療的女性的生活質量和成本效益可能沒有顯著的益處從它是相當可觀的。(要了解有關MammaPrint BluePrint乳腺癌復發和分子亞型試劑盒的更多信息，請訪問：www.agendia.com/diagnostic-products（僅限歐洲）)Agendia receives CE mark for MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping KitIRVINE, CA, AMSTERDAM, NETHERLANDS – 21 March 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation sequencing (NGS)-based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit is now CE marked, enabling the Company to commercialize the device in Europe.Dr. Marjolaine Baldo, Commercial Vice President, EMEA at Agendia said:“Obtaining the CE mark for the MammaPrint BluePrint Kit is a huge milestone. For the first time, prestigious cancer centers across Europe will be able to run MammaPrint and BluePrint in their own labs, using their existing NGS instruments. As a result, patients will have better access to these vital tests and the significant benefits that they bring in personalizing breast cancer management.“We are proud of the drive, dedication and expertise of our team, partners and co-validation centers who, in recognizing the need for a decentralized solution, have worked tirelessly to develop, validate and deliver this important device to the market. We look forward to collaborating with leading breast cancer centers to provide them with these tools, enabling them to offer breast cancer risk-of-recurrence testing in-house.”MammaPrint analyzes 70 genes most associated with breast cancer recurrence to provide a binary Low or High Risk of cancer recurrence result, while BluePrint analyzes 80-genes which classify a patient’s breast cancer into functional molecular subtypes. This new device, which combines both MammaPrint and BluePrint, can aid physicians in personalizing treatment management decisions for their patients by identifying women with early-stage breast cancer who are at a genomic Low or High Risk for distant metastasis within five years.The MammaPrint BluePrint Kit is an RNA-sequencing based version of Agendia’s existing MammaPrint and BluePrint tests, which are currently performed centrally at the Company’s CLIA-certified and CAP-accredited laboratories in Irvine, CA and Amsterdam, the Netherlands. The Kit was developed in partnership with Agilent Technologies using their SureSelect target enrichment system and with Bluebee, who provided the secure and convenient data processing solution for clinicians.Dr. William Audeh, Chief Medical Officer at Agendia, said:“The clinical utility of the MammaPrint test has been demonstrated by the landmark MINDACT trial. It showed, with the highest level of clinical evidence, that 46% of patients identified as high risk for recurrence according to clinical-pathological factors and who would therefore be typical candidates for adjuvant chemotherapy were reclassified as Low Risk by MammaPrint, indicating that they were unlikely to benefit from chemotherapy.“With breast cancer being the most common cancer in women, affecting one in eight in Europe and with almost 500,000 new cases a year, the quality-of-life and cost benefits of identifying women previously selected for chemotherapy that may not have significant benefit from it is considerable.”2,3To learn more about the MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit, visit: www.agendia.com/diagnostic-products (Europe only)1 Cardoso F, van’t Veer LJ, Bogaerts J et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375: 717-29.2 Curado MP, et al. Cancer Incidence in Five Continents, Vol. IX, IARC Scientific Publications No. 160. IARCPress: Lyon: 2007.3 Ferlay J, et al.e. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed 04 August 2017 http://www.ybe.com.tw/hot_86930.html http://www.ybe.com.tw/hot_86930.html 172707 Fri, 04 Mar 2016 16:52:54 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測依據患者個人乳癌腫瘤基因進行分析而成功改變治療計畫來自美國加州的Julieta強烈建議與她同樣感到困擾的乳癌患者，選擇「欣扶妳成功改變治療計畫MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測」，因為這個檢測成功的改變了她未來的人生。 (備註：個別患者各有其特殊狀況應由患者及其主治醫師共同決定。) http://www.ybe.com.tw/hot_172707.html http://www.ybe.com.tw/hot_172707.html 172709 Fri, 04 Mar 2016 16:54:06 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測選擇欣扶妳乳癌腫瘤基因雙效檢測後發現自己原來是屬於高風險患者美國南達科他州的Nicole表示：她的病理報告呈現出的是低風險，幸好她選擇做了「MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測」，發現她自己原來是高風險的族群。因此，醫師給她更積極的治療方案，她鬆了一口氣，她說：「長遠來看，非常有可能是MammaPrint救了我一命呢!」 (備註：個別患者各有其特殊狀況應由患者及其主治醫師共同決定。) http://www.ybe.com.tw/hot_172709.html http://www.ybe.com.tw/hot_172709.html 172710 Fri, 04 Mar 2016 16:54:47 +0800 MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測報告顯示為高風險的她下定決心勇敢接受治療美國加州的Mary一直在考慮要做哪個治療，需要乳房切除術嗎？是不是需要化療？還是要考慮其他的治療方案嗎？透過「MammaPrint+BluePrint欣扶妳乳癌腫瘤基因雙效檢測」報告顯示為高風險的她，下定決心勇敢接受治療。而她對於根據她個人乳癌腫瘤基因而量身制定的治療計畫感到滿意！ (備註：個別患者各有其特殊狀況應由患者及其主治醫師共同決定。) http://www.ybe.com.tw/hot_172710.html http://www.ybe.com.tw/hot_172710.html 68836 Fri, 21 Mar 2014 15:33:49 +0800 改善的契機：過度診斷與過度治療癌症 Laura J. Esserman, MD, MBA (1); Ian M. Thompson, Jr, MD (2); Brian Reid, MD, PhD (3)(1) University of California, San Francisco (2) University of Texas Health Science Center at San Antonio (3) Fred Hutchinson Cancer Research Center, Seattle, Washington JAMA. 2013;310(8):797-798. doi:10.1001/jama.2013.108415.RASTER文獻下載乳癌亞型基因檢測幫助判斷早期乳癌患者做前置式(術前)輔助治療是否有好處Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapyStefan Glück, Femke de Snoo, Justine Peeters,Lisette Stork-Sloots, George SomloBreast Cancer Research Treatment 2013 Jun;139(3):759-67文獻下載Dr. Stefan Glück 解說乳癌亞型如何影響個人化治療 http://www.ybe.com.tw/hot_68836.html http://www.ybe.com.tw/hot_68836.html 68834 Fri, 21 Mar 2014 15:33:01 +0800   http://www.ybe.com.tw/hot_68834.html http://www.ybe.com.tw/hot_68834.html